Summit receives Japanese rights to Neuralstem’s neurogenic compound NSI189
Executive Summary
Neuralstem Inc. (commercial production of brain and spinal cord stem cells) has licensed Summit Pharmaceuticals International Corp., the pharmaceutical R&D and services division of diversified company Sumitomo Corp., exclusive Japanese rights to develop and sell its NSI189, a Phase Ia compound for major depression that targets hippocampal neurogenesis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice